Jonathan Weltz, DO
Hematology & Oncology · Delray Beach, FLNPI 1376076158
Payments from drug & device makers
Across 132 payments — averaging $78.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$3K
- Karyopharm Therapeutics Inc.$3K
- Daiichi Sankyo Inc.$898
- Johnson & Johnson$302
- Gilead$265
- Pfizer$261
- plus $3K from 32 others
What the payments were for
- Consulting fees$6506%
- Speaking & faculty fees$2,00019%
- Travel & lodging$3,73536%
- Food & beverage$3,84237%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 4 | $3,070 |
| Karyopharm Therapeutics Inc. | 2 | $2,888 |
| Daiichi Sankyo Inc. | 12 | $898 |
| Johnson & Johnson | 10 | $302 |
| Gilead(2 entities) | 3 | $265 |
| Pfizer | 7 | $261 |
| AstraZeneca(2 entities) | 9 | $222 |
| Sanofi | 8 | $197 |
| Incyte Corporation | 6 | $172 |
| GSK | 4 | $167 |
| Genentech USA, Inc. | 5 | $160 |
| Amgen | 1 | $125 |
| Seagen Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 6 | $124 |
| Merck | 5 | $120 |
| Astellas Pharma US Inc | 5 | $115 |
| Rigel Pharmaceuticals, Inc. | 3 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $87 |
| Boehringer Ingelheim | 3 | $82 |
| Eisai Inc. | 3 | $82 |
| Exelixis Inc. | 4 | $79 |
| Deciphera Pharmaceuticals Inc. | 3 | $73 |
| AVEO Pharmaceuticals, Inc. | 2 | $72 |
| Adaptive Biotechnologies Corporation | 2 | $59 |
| Tersera Therapeutics LLC | 2 | $59 |
| Lilly USA, LLC | 2 | $48 |
| Array Biopharma Inc | 2 | $47 |
| Sobi, Inc | 1 | $36 |
| Caris MPI, Inc. | 1 | $31 |
| Mirati Therapeutics, Inc. | 1 | $29 |
| Novartis | 1 | $27 |
| Bayer | 1 | $23 |
| Beigene USA, Inc. | 1 | $22 |
| EMD Serono, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,327 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 38 | $590,065 |
| VenclextaVenetoclax | 29 | $452,782 |
| BrukinsaZanubrutinib | 31 | $382,565 |
| JakafiRuxolitinib Phosphate | 20 | $372,503 |
| RevlimidLenalidomide | 17 | $324,765 |
| ImbruvicaIbrutinib | 12 | $185,424 |
| CalquenceAcalabrutinib Maleate | 13 | $97,659 |
| EliquisApixaban | 31 | $23,749 |
| XareltoRivaroxaban | 13 | $8,264 |
| Hydroxyurea | 49 | $1,422 |
| Acyclovir | 30 | $624 |
| Prednisone | 28 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $22 | $382,56531 claims |
| Incyte CorporationJakafi | $172 | $372,50320 claims |
| Bristol Myers SquibbRevlimid | $20 | $324,76517 claims |
| AstraZenecaCalquence | $222 | $97,65913 claims |
| PfizerEliquis | $261 | $23,74931 claims |
| Johnson & JohnsonXarelto | $302 | $8,26413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Delray Beach
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.